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Myocardial inflammation and energetics 
by cardiac MRI: a review of emerging techniques
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Abstract 
The role of inflammation in cardiovascular pathophysiology has gained a lot of research interest in recent years. Car-
diovascular Magnetic Resonance has been a powerful tool in the non-invasive assessment of inflammation in several 
conditions. More recently, Ultrasmall superparamagnetic particles of iron oxide have been successfully used to evalu-
ate macrophage activity and subsequently inflammation on a cellular level. Current evidence from research studies 
provides encouraging data and confirms that this evolving method can potentially have a huge impact on clinical 
practice as it can be used in the diagnosis and management of very common conditions such as coronary artery 
disease, ischaemic and non-ischaemic cardiomyopathy, myocarditis and atherosclerosis. Another important emerging 
concept is that of myocardial energetics. With the use of phosphorus magnetic resonance spectroscopy, myocardial 
energetic compromise has been proved to be an important feature in the pathophysiological process of several con-
ditions including diabetic cardiomyopathy, inherited cardiomyopathies, valvular heart disease and cardiac transplant 
rejection. This unique tool is therefore being utilized to assess metabolic alterations in a wide range of cardiovascular 
diseases. This review systematically examines these state-of-the-art methods in detail and provides an insight into the 
mechanisms of action and the clinical implications of their use.
Keywords: Cardiovascular magnetic resonance (CMR), Ultrasmall superparamagnetic particles of iron oxide (USPIO), 
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Background
With more research focus being shifted in the complex 
pathophysiology of cardiovascular disease it is of para-
mount importance that we have the appropriate diag-
nostic techniques to identify the complicated disease 
processes that lie behind the symptoms. Cardiac energy 
metabolism in cardiovascular disease represents the 
foundation of the pathophysiological mechanisms that 
lie behind the disease processes and phenotypes and can 
guide the treatment strategy. Better understanding of 
cardiac metabolism and energetics can aid the diagno-
sis, prevention and management of each specific disease 
process. Cardiovascular Magnetic Resonance (CMR) 
has proved to be a powerful tool for this exact purpose 
with novel methods allowing for early accurate diagno-
sis and establishing appropriate therapeutic targets in a 
timely manner. In this review, we illustrate the critical 
role of state-of-the-art CMR methods in the assessment 
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Ultrasmall superparamagnetic particles of iron oxide CMR 
for myocardial inflammation
Inflammation is an expanding risk factor for cardiovas-
cular disease [1] and involved in a plethora of condi-
tions including atherosclerosis [2], myocardial infarction 
[3] cardiomyopathies [4, 5], myocarditis [6] and valve 
disease [7]. With increasing advancements, CMR has 
enabled non-invasive assessment of inflammation at a 
myocardial level using short τ inversion recovery (STIR) 
sequences, late gadolinium enhancement (LGE), T1 and 
T2 mapping, negating the need for invasive myocardial 
biopsy in many patients. However, such sequences do not 
allow us to detect cellular inflammation. At this cellular 
level, macrophages play a major part in both the initia-
tion and maintenance, as well as resolution of inflam-
mation [8]. Identifying therefore macrophage activity 
is crucial as not only can it allow accurate diagnosis 
and monitoring of disease progression, but importantly 
it can enable targeted therapeutic interventions, both 
on macrophages and their by-products. This can allow 
control of the inflammation and thus slowing down, or 
even halting completely, specific cardiovascular disease. 
More recently, Ultrasmall superparamagnetic particles 
of iron oxide (USPIO) have been used successfully to 
assess cellular inflammation safely [9]. USPIO consist 
of nanoparticles with a diameter of < 50 nm which have 
the ability to be taken up by tissue-resident macrophages 
and neutrophils [3, 10]. These particles shorten the T2* 
relaxation time of tissues in which they acscumulate and 
therefore their impact can be assessed in T2*-weighted 
imaging and quantified by measuring the changes in the 
T2* and R2* values (R2* = 1/T2*) [10, 11]. Recently, the 
USPIO methodology has been validated with histologi-
cal confirmation that USPIO accumulates in active car-
diac macrophages and identifies areas of active cardiac 
inflammation [11]. The pathophysiology of USPIO and 
how USPIO CMR can be undertaken has been exten-
sively reviewed elsewhere [3] and in this section we will 
focus on the potential clinical applications.
Multiple studies have assessed the role of USPIO CMR 
in STEMI or NSTEMI [11–15] and even following cor-
onary artery bypass graft (CABG) [16]. These studies 
showed an increase in USPIO R2* in the infarcted and 
peri-infarct myocardium and this could be seen up to 
two weeks from the acute event (see Fig.  1). Some also 
showed that even the remote myocardium had a smaller 
increase in USPIO R2* lending therefore support that 
macrophage activation in the remote myocardium can 
effectively lead to myocardial damage. Interestingly, the 
study on CABG patients did not reveal significant dif-
ferences in USPIO R2* indicating that perhaps the myo-
cardial injury following CABG is less likely to be mainly 
driven by inflammation [16].
Whilst the role of oedema in Takotsubo cardiomyopa-
thy had been recognized [17], one clinical study utiliz-
ing USPIO CMR enabled us to confirm for the first time 
that macrophage activity is the driving force. Fifty-five 
patients with acute Takotsubo cardiomyopathy were 
included as well as controls, and their USPIO CMR 
acutely showed greater differences between pre and post 
USPIO T2* in both the ballooning as well as the non-
ballooning myocardial segments. At five months, this dif-
ference was no longer seen, indicating complete recovery 
of cellular inflammation. Interestingly, the patients also 
underwent 31P-CMR spectroscopy, which showed mark-
edly reduced energetic state acutely, which however did 
not return to normal even at five months. The combina-
tion of the two methods allowed us to identify the cause 
of the acute decompensation (cellular inflammation) 
but also appreciate why some patients with Takotsubo 
cardiomyopathy continue to have long-lasting sympto-
matic and functional impairment (decreased energet-
ics) [18] thus enabling to focus further research either in 
managing inflammation during the acute phase, or the 
decreased energetics in the longer term.
The role of inflammation in myocarditis is well 
acknowledged, and indeed reflected in the recent Expert 
Recommendation with the Revised Lake Louise Crite-
ria [19] whereby the oedema sequences, LGE and mul-
tiparametric parametric mapping play a crucial role in 
the diagnosis. However, cellular inflammation in myo-
carditis has been less well established or studied. The 
largest USPIO CMR study of acute myocarditis included 
only nine patients [20] with imaging results as shown in 
Fig. 2, but it failed to reveal any differences in USPIO R2* 
between the patients and controls, even when only the 
LGE positive myocardial areas were considered. Simi-
larly, a much smaller study, including only five patients 
with acute myocarditis [21] likewise failed to show any 
significant differences compared to controls in USPIO 
R2*/R1. This is perhaps unexpected and would indi-
cate that macrophages are not the primary medium of 
inflammation in myocarditis, unlike reported previously 
by histological studies which confirmed predominantly 
macrophage-rich inflammation associated with myocyte 
damage in areas of LGE [22]. It should be considered 
however, that even between them, the two studies only 
included 14 patients. Coupled with the known blooming 
artefacts which are more prominent in the inferolateral 
myocardium, which is the most common site of myo-
carditis, it might still be a possibility that USPIO simply 
failed to detect macrophage activity and further work is 
warranted.
The potential role of inflammation in triggering an 
ischaemic cardiomyopathy has long been considered 
[23]. However, many studies targeting inflammation 
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Fig. 1 a Patient 1 week post left anterior descending artery infarction with extensive, anterior wall, transmural, mid-ventricle late gadolinium 
enhancement (LGE) on T1-weighted images (left column), homogeneous myocardial T2 ∗ values before erumoxytol (middle column), but intense 
dark ferumoxytol uptake in the region of the infarction 24 h post ferumoxytol infusion (right column). b Same patient with anteroapical, transmural 
LGE, again homogeneous T2 ∗ myocardial values at base, but clear ferumoxytol uptake on T2 ∗ scanning in the region of the LGE 24 h after 
ferumoxytol infusion. Image reproduced with permission from Merinopoulos et al. [10]
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therapeutically in this setting have been negative. Could 
inflammation however still play a role in non-ischaemic 
cardiomyopathy? A recent study involving only seven 
patients, studied with USPIO CMR on average 1.4 years 
following their acute myocardial infarction showed 
that both infarcted and non-infarcted myocardium had 
higher R2*. This would lend support to the notion that 
inflammation could possibly explain why only some 
patients progress to severe cardiomyopathy and others 
do not, even with similar index coronary events.
Multiple studies utilising USPIO MRI have investi-
gated the role of inflammation in carotid atheroscle-
rosis, aortic aneurysms and even monitor the effect 
of statins on atherosclerosis regression [24, 25]. These 
studies confirmed macrophage activity in carotid 
arteries which appeared independent from the degree 
of stenosis, suggesting therefore that both are inde-
pendent risk factors. In addition, high dose statin 
therapy also showed a reduction in USPIO-defined 
inflammation in the carotids, indicating that USPIO 
can also potentially act as the investigation of choice for 
early endpoints. Whether USPIO and 18F-FDG corre-
late well, or whether they might indicate different parts 
of inflammation remains unclear as to date the studies 
are conflicting [26, 27]. USPIO MRI can be helpful in 
other vascular structures such as the abdominal aorta 
(see Fig. 3), where it can potentially be used to identify 
patients at higher risk of aneurysmal expansion (than 
based on diameter alone) and in turn inform the need 
and timing for surgery [28].
Fig. 2 An example of a patient with acute myocarditis showing sub-epicardial LGE, inferiorly and inferolaterally on 4-chamber and 3-chamber 
views (left) but no evidence of ferumoxytol uptake within the regions displaying LGE 24 h following infusion (right). CMR = cardiac magnetic 
resonance; LGE = late gadolinium enhancement. Image reproduced with permission from Merinopoulos et al. [10]
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The clinical application of USPIO is further promoted 
by their safety profile. It has been demonstrated that it is 
a safe alternative to gadolinium-based contrast agents in 
patients with chronic kidney disease at risk for nephro-
genic systemic fibrosis, and therefore can safely be used 
in this patient cohort [29]. Perhaps one of the main safety 
concerns is the risk of acute hypersensitivity allergic reac-
tion, a rare but potentially life-threatening complication 
for which the U.S. Food and Drug Administration issued 
a boxed warning about the use of ferumoxytol a few years 
ago [30]. Since then, however, the safety profile of these 
agents has further improved, and large studies have suc-
cessfully demonstrated and support their safe use in clin-
ical practice [9, 31].
In summary therefore, USPIO MRI is an emerging 
safe method, to assess cellular inflammation. Whilst at 
the moment its role is mainly limited to research, future 
applications could include diagnostic as well as serial 
imaging applications, monitoring the response to treat-
ment, or even guiding the timing of intervention.
Phosphorus magnetic resonance spectroscopy 
and myocardial energetic impairment
Magnetic resonance spectroscopy (MRS) is an opti-
mal non-invasive tool used commonly to analyse 
cardiac energy metabolism both in the clinical and 
pre-clinical setting. In the heart, ATP delivery can 
occur through the creatine kinase (CK) system, which 
catalyzes the following reversible reaction: Phosphocre-
atine + ADP + H +  ↔ Creatine + ATP. The relative con-
centration of phosphocreatine to ATP (PCr/ATP) is a 
marker of the myocardium’s ability to convert substrate 
into ATP for active processes, and a representantive 
index of the myocardial energetic state. Phosphorus mag-
netic resonance spectroscopy (31P-MRS) allows accu-
rate—yet non-invasive—evaluation of the myocardial 
PCr/ATP ratio [32] as well as absolute levels of high-
energy phosphates [33]. Using this technique, studies 
have shown myocardial energetic compromise to be a 
feature of diabetic cardiomyopathy [34–36] inherited 
cardiomyopathies [37, 38], valvular heart disease [39], 
cardiac transplant rejection [40]. In practice, at clinical 
field strengths (1.5 and 3 Tesla), a cardiac 31P spectrum is 
obtained from a 3D-localised myocardial voxel at specific 
acquisition times predefined by the user [41]. Acquisition 
times may vary with longer acquisition times required if 
small voxels and / or high signal to noise ratio is wanted 
[41]. 31P-MRS has inherently low signal to noise ratio 
and has low sensitivity to metabolites at low concentra-
tions [41, 42]. This represents the main limitation of this 
technique as long acquisition time is required to achieve 
adequate signal to noise ratio [41, 42]. However, develop-
ments over the recent years are tackling this issue with 
the development of fast techniques mapping the phos-
phate metabolites [41].
Over the last decade there has been notable progress 
in the field with the attempt to analyse the cardiac meta-
bolic phenotype in detail non-invasively, and to deline-
ate the relationship between the metabolic remodelling 
of the myocardium and the structural and functional 
changes. Due to the constantly varying cardiac work-
loads, efficient matching of energy supply to demand is 
essential for maintaining normal cardiac function [43] 
and myocardial metabolism is profoundly affected by 
changes in cardiac workload. The onset of exercise trig-
gers a rapid increase in demand for substrate, and oxygen 
[44]. Rapid changes in the energy demand can be dealt 
by the fast responsive mechanisms of the healthy myo-
cardium, [45], some of which include increased rates of 
phosphotransferase reactions [36, 46]. Assessing cardiac 
energetic response to exercise by 31P-MRS, aggravation 
of the pre-existing energetic insufficiency in patients with 
type 2 diabetes (T2D) was shown during increased work-
load (Fig.  4) [36]. Further, despite having no significant 
obstructive CAD, mean myocardial perfusion reserve 
index (MPRI) was significantly reduced in these patients 
[47, 48]. Pointing to the importance of an appropriate 
hyperaemic response during exercise to maintain cellu-
lar energy metabolism, significant correlations between 
Fig. 3 Classification of aneurysms based on uptake of ultrasmall 
superparamagnetic particles of iron oxide (USPIO). MRI is performed 
at baseline then 24 h following intravenous administration of USPIO. 
USPIO causes a reduction in T2* and can be quantified by comparing 
co-registered T2* images pre- and post- USPIO administration, 
presented as change in T2* represented as colour maps (as above). 
’Positive uptake’ of USPIO is denoted by the red colour (thresholded 
at change in T2* of at least 71% between pre-and post-USPIO 
administration), whereas blue denotes areas of no positive uptake. Of 
note, ‘significant’ uptake (i.e. USPIO positive) is defined as at least one 
focal area of USPIO uptake corresponding to 10 or more contiguous 
voxels of positive signal change at the aneurysm wall; USPIO uptake 
at the periluminal area is not thought to be clinically significant. 
Image courtesy of Dr Rachel Forsythe, University of Edinburgh
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MPRI with exercise energetics were demonstrated in 
patients with T2D [47]. While similar reductions in myo-
cardial PCr/ATP during exercise was detected in patients 
with hypertrophic cardiomyopathy (HCM), in HCM this 
exacerbation of the energetic impairment was independ-
ent of perfusion reserve, as well as the degree of myocar-
dial fibrosis or hypertrophy [37]. No significant changes 
in myocardial energetics with exercise activity was 
detected in comparison to the rest values in patients with 
dilated cardiomyopathy [49].
The CK system can also act as a buffer to dimin-
ish the differences in ATP and ADP levels, a feature 
which is crucial in maintaining the free energy of ATP 
hydrolysis in the cytosol. More recently, turnover 
Fig. 4 Rest and exercise myocardial 31P-MR spectra in a healthy volunteer (top row) and a T2D patient, suggesting a pre-existing energy deficit in 
the diabetic heart. Image reproduced with permission from Levelt et al. [47].
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rates of high-energy phosphates (CK Flux) in humans 
have also been measured with the saturation transfer 
method [50]. These dynamic turnover rates seem to 
be even stronger predictors of outcome in heart fail-
ure than steady-state concentrations [51]. Utilising this 
method, in a cohort of obese individuals and no other 
cardiac comorbidities, the myocardial CK reaction 
rate at rest was shown to be enhanced, preserving ATP 
delivery even with reduced PCr/ATP [52]. However, 
during augmented workload, ATP delivery through 
CK was not increased in the obese cohort in contrast 
with what is detected in non-obese controls suggest-
ing that lower ATP delivery occurs during stress in 
obesity. This finding was shown to be associated with 
reduced systolic augmentation and exercise tolerance 
in patients with obesity. Highlighting the importance 
of myocardial energy supply through CK as a poten-
tial treatment focus to improve symptoms in obesity-
related heart disease, weight loss has reversed these 
energetic changes. Similarly, the total CK flux capacity 
was recently shown to be reduced in patients with aor-
tic stenosis (AS), with a reduced resting CK flux evi-
dent already in patients with moderate AS even with 
preserved LV systolic function [53]. These findings 
imply that moderate AS is associated with consider-
ably impaired energetic state of the myocardium which 
is already established and a decline in the CK flux itself 
is not essential for the shift towards the systolic failure.
Finally, cellular metabolism can now by measured 
in vivo and in real-time thanks to the recent advance-
ment of hyperpolarized 13C MRS.. Rider et al. success-
fully utilised hyperpolarized [1-13C] pyruvate MRS to 
assess downstream metabolism of [1-13C] pyruvate 
via PDH (pyruvate dehydrogenase, [13C] bicarbonate), 
lactate dehydrogenase ([1-13C] lactate), and alanine 
transaminase ([1-13C] alanine), in 5 patients with T2D 
and 5 controls at baseline, and repeated these meas-
urements in 5 of these participants (3 T2D, 2 controls) 
45  min after a 75  g oral glucose challenge [54]. They 
showed metabolic flux through cardiac pyruvate dehy-
drogenase (PDH) was noticeably declined in the indi-
viduals with T2D compared to controls. In addition, 
they have also detected a major increase in metabolic 
flux through PDH 45 min after the oral administration 
of 75 g of glucose in patients with T2D and in controls. 
This was the first study to show that physiological 
and pathological variations in PDH flux in the human 
heart can be evaluated with the use of hyperpolarized 
pyruvate, highlighting in this way that this method has 
the potential to assess metabolic shifts in a variety of 
cardiovascular disorders.
Conclusion
The unique CMR methods discussed in this review are 
without doubt a pillar that can contribute substantially 
to future research and clinical practice.
USPIO CMR represents a robust novel method that 
assesses myocardial inflammation on a cellular level by 
identifying macrophage activity. It can be applied in a 
variety of diseases, including ischaemic and non-ischae-
mic cardiomyopathies, enabling in this way not only 
precise diagnosis and monitoring, but also targeted ther-
apeutic interventions early in the disease process. MRS 
is another state-of-the-art tool ideal for the non-invasive 
assessment of cardiac energy metabolism, with its poten-
tial expanding in the evaluation of metabolic alterations 
in various different cardiovascular pathological pro-
cesses. Further research and clinical studies are needed in 
order to explore how these novel CMR techniques com-
pare with other imaging methods, such as positron emis-
sion tomography, and what clinical information they may 
add in the pathophysiological processes of a wide spec-
trum of cardiovascular diseases [55].
Considering that tissue inflammation and myocardial 
energetics play a key role in the pathophysiology of a wide 
range of cardiovascular diseases, these novel CMR meth-
ods and techniques are proving to meet the research and 
clinical expectations in assessing the disease processes on 
a cellular level. This, in turn, can provide clear insights 
not only in the diagnosis but also in the risk stratification 
and management strategies adapted in the future.
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